Cerus Corporation Reports Strong Growth and Sets Ambitious 2026 Targets

Cerus US1570851014

Cerus Corporation has concluded a successful fiscal year, driven by the international rollout of its blood safety systems. The company, whose technologies are now employed in approximately 40 countries, has outlined confident projections for the coming year, aiming to maintain its positive momentum.

• Preliminary 2025 Product Revenue: $206.1 million (+14%)
• Full-Year IFC Revenue: $16.7 million (+80%)
• 2026 Product Revenue Guidance: $224 million to $228 million
• Next Quarterly Report: Expected February 19, 2026

Looking ahead, management anticipates the current growth trajectory will continue. For the full 2026 fiscal year, Cerus has provided product revenue guidance in the range of $224 million to $228 million. This forecast represents a projected increase of 9% to 11% over the prior year's unaudited results.

A significant portion of this growth is expected to come from the higher-margin INTERCEPT Fibrinogen Complex (IFC) business. The company is targeting IFC revenue between $20 million and $22 million for 2026, which would equate to a growth rate of 20% to 30%. Achieving these objectives is linked to continued commercial expansion and advancements in the product pipeline.

Fourth Quarter and Full-Year 2025 Performance

The company's preliminary figures reveal a strong finish to 2025. Fourth-quarter product revenue reached $57.8 million, marking a 14% year-over-year increase. The IFC segment was a standout performer during the period, with quarterly revenue of $4.2 million representing a jump of approximately 40% compared to the same quarter in 2024.

The full-year picture for IFC is even more striking. Revenue surged roughly 80% to $16.7 million for the entirety of 2025. These results validate the company's strategic focus on expanding global access for its specially treated blood components. Reflecting on the year, company leadership described 2025 as a pivotal period for enhancing patient care worldwide.

Investors are awaiting the final, audited financial statements for fiscal year 2025. The next key milestone is scheduled for February 19, 2026, when Cerus is expected to release its complete annual report.